| 摘要: |
| 抑制性共刺激分子程序性死亡因子1（PD-1）/程序性死亡因子配体1（PD-L1）是重要的负性免疫调节分子，在机体适应性细胞免疫中发挥着重要作用。表达PD-L1的肿瘤细胞可与T细胞表面受体分子PD-1特异性结合，从而影响T细胞的活化与分化，并抑制T细胞的抗肿瘤免疫杀伤活性。目前，已有多种靶向PD-1/PD-L1免疫检查点的药物应用于临床，并在不同类型的肿瘤治疗中显示出良好疗效。本文就PD-1/PD-L1的分子结构、表达特点、上调影响因素，以及其在促进肿瘤生长、免疫逃逸、肿瘤免疫治疗中的作用等方面的研究进展作一综述。 |
| 关键词: 程序性死亡因子1 程序性死亡因子配体1 肿瘤 免疫疗法 |
| DOI：10.16781/j.0258-879x.2017.09.1190 |
| 投稿时间：2017-02-12修订日期：2017-05-08 |
| 基金项目:国家自然科学基金（81272668，81272669）. |
|
| Programmed death 1/programmed death ligand 1 signaling pathway in tumor immunotherapy:an update |
| WANG Wen-chao1,2,WANG Yu1,2,SHI Le-hua2,YIN Zheng-feng1* |
(1. Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China;
2. Department of Hepatic Surgery(Ⅳ), Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| As negative immune regulatory molecules, the inhibitory co-stimulatory molecules programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) play important roles in the adaptive cellular immunity. PD-L1 expressed in tumor cells is involved in regulating T cell activation and differentiation and inhibiting the anti-tumor immune activity of T cell through specific binding with the receptor molecule PD-1 on T cells. Currently, a variety of agents targeting the immune checkpoints of PD-1/PD-L1 have been used in clinic, which have exhibited long-lasting effect in treatment for different types of tumors. In this review, we summed up the molecular structure, expression features, factors influencing upregulation of PD-1/PD-L1, and their roles in promoting tumor growth and escaping from immune system and tumor immunotherapy. |
| Key words: programmed death 1 programmed death ligand 1 neoplasms immunotherapy |
